AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰 Latest breakthroughs
🗺️ Disease Atlas · Infectious disease

dengue disease

Dengue fever (DF), caused by dengue virus, is an arboviral disease characterized by an initial non-specific febrile illness that can sometimes progress to more severe forms manifesting capillary leakage and hemorrhage (dengue hemorrhagic fever, or DHF) and shock (dengue shock syndrome, or DSS).

🔔 Follow weekly
🧬2223genes / proteins with evidence
💊20drugs and clinical candidates
🧪12+recruiting trials worldwide
✅4phase 3
📈2phase 2/3
🦠

Understand dengue disease

Infections · Germs against the immune system
🎓 Learn more

What it is

Dengue is a viral infection. It can be caused by four related viruses. You can get it if an infected mosquito bites you. It is common in warm, wet areas of the world. Although rare, it can be found in some parts of the United States. Outbreaks are more common during rainy seasons.

How does dengue spread?

Dengue spreads to people through the bite of an infected mosquito. It does not spread directly from person to person. However, the infection can be passed to the baby during pregnancy. In rare cases, it can spread through a blood transfusion, organ transplant, or needle stick injury (an accidental injury from a used needle)..

From MedlinePlus: Dengue (US National Library of Medicine) ↗

🦠 Infections: Infectious diseases are caused by germs - bacteria, viruses, parasites or fungi - that enter the body and multiply. Examples are tuberculosis, malaria and dengue.

❓ Why it happens

  • Germs spread through the air, water and food, by touch, through blood, or by insects such as mosquitoes.
  • A weak immune system, crowded housing, poor sanitation and lack of vaccines raise the risk.

🫀 What it does to the body

  • Germs damage the tissues they live in - the lungs in tuberculosis, the blood in malaria.
  • The immune system fights back, causing fever and inflammation.

🧱 Why it is hard to cure

  • Germs evolve resistance to medicines, as in drug-resistant tuberculosis and malaria.
  • Some diseases still have no vaccine, or only a partly protective one.
  • The people most affected are often the hardest to reach with tests and treatment.

🚀 What research is trying now

  • New antibiotics and shorter tuberculosis treatments.
  • Malaria vaccines now recommended by the World Health Organization for children.
  • AI to design new antimicrobial molecules, and faster tests that also detect drug resistance.

General information about infections, reviewed by people; it does not describe any one person. Below: the evidence for dengue disease itself.

🤖

AI briefing

Where the science on dengue disease stands, from the evidence on this page

AI reads the targets, drugs, trials and papers below and writes where the science stands — every claim cited. It is shared with everyone who opens dengue disease.

🎯

Top targets

Genes and proteins ranked by Open Targets evidence (0-1)
APOA1 apolipoprotein A1PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.58
HAVCR1 hepatitis A virus cellular receptor 1PROTACantibody🧊 AlphaFold structure ↗ 0.56
YBX1 Y-box binding protein 1PROTACantibody🧊 AlphaFold structure ↗ 0.55
CD209 CD209 moleculePROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.53
MAGT1 magnesium transporter 1PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.52
VIM vimentinPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.52
PROS1 protein SPROTACantibody🧊 AlphaFold structure ↗ 0.51
STT3B STT3 oligosaccharyltransferase complex catalytic subunit BPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.51
HSPA5 heat shock protein family A (Hsp70) member 5PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.51
STT3A STT3 oligosaccharyltransferase complex catalytic subunit APROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.51
AXL AXL receptor tyrosine kinasePROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.51
GAS6 growth arrest specific 6PROTACantibodyother🧊 AlphaFold structure ↗ 0.51
DDOST dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-ca…PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.51
HSPA8 heat shock protein family A (Hsp70) member 8PROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.51
TUSC3 tumor suppressor candidate 3PROTACantibody🧊 AlphaFold structure ↗ 0.51

Green labels: what the target is known to be druggable by. The score combines genetics, somatic mutations, drugs, expression and literature.

💊

Drugs and candidates

Every medicine linked to dengue disease, by how far it has got
In phase 2 / 3 · 16
AcetylcysteinePhase 3
Albumin HumanPhase 3
BaricitinibTyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitorPhase 3
DexamethasoneGlucocorticoid receptor agonistPhase 3
Emetine HydrochloridePhase 2/3
MontelukastCysteinyl leukotriene receptor 1 antagonistPhase 2/3
Show all 16
Chimeric Yellow Fever Dengue Virus, Live AttenuatedPhase 2
FenretinidePhase 2
Ic14Monocyte differentiation antigen CD14 inhibitorPhase 2
IvermectinGlutamate-gated chloride channel modulatorPhase 2
MelatoninMelatonin receptor agonistPhase 2
MolnupiravirPhase 2
MosnodenvirPhase 2
RemdesivirRNA-directed RNA polymerase L inhibitor; Replicase polyprotein 1ab inhibitorPhase 2
ResomelagonPhase 2
ZanamivirNeuraminidase inhibitorPhase 2
Early trials · 4
CelgosivirAlpha glucosidase inhibitorPhase 1/2
MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphat…Phase 1/2
ModipafantPhase 1/2
BalapiravirRNA-directed RNA polymerase inhibitorPhase 1
🧪

Recruiting trials

Worldwide, open to new patients now
Innovative Multidisciplinary Strategies for Combating Severe DengueNCT06751836 · n/a · 📍 Guatemala CityCharacterisation of Dengue Vaccine-induced Specific Immunity in Vaccinees With and Without Prior Exposure to …NCT06776692 · n/a · 📍 NegrarAdaptive Dengue Antiviral Platform TrialNCT06551844 · Phase 2 · 📍 Kuala LumpurMolecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell PatientsNCT07000747 · n/a · 📍 Pointe-à-PitreClinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)NCT06917001 · Phase 2 · 📍 Belo HorizonteRisk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus InfectionNCT07007585 · n/a · 📍 Piedras NegrasEfficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)NCT05631405 · NA · 📍 BangkokMetabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study)NCT05400824 · n/a · 📍 La RéunionGut Leakage' in DengueNCT07602920 · n/a · 📍 ChittagongPhase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic,…NCT07706686 · Phase 1 · 📍 BethesdaA Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue FeverNCT06006559 · Phase 2 · 📍 ManausZanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)NCT04597437 · Phase 2 · 📍 Barranquilla Search more trials →
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy